OBJECTIVES:~Primary~Determine the response rate (complete and partial) in patients with recurrent or refractory angioimmunoblastic T-cell lymphoma treated with cyclosporine.~Secondary~Determine the disease-free, progression-free, and overall survival of patients treated with this drug.~Determine the toxicity of this drug in these patients.~OUTLINE: Patients receive oral cyclosporine twice daily for up to 36 weeks in the absence of unacceptable toxicity or disease progression during weeks 1-6. Patients experiencing disease progression during weeks 7-36, receive an additional 36 weeks of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year.~PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study within 2.5 years.
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma.~PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.